Clinical Trials Initiated and Significant Milestone Reached in the Collaboration Between Karo Bio and Merck & Co., Inc.
clinical trials have been initiated for the most advanced compound in the drug discovery and development collaboration between Merck & Co., Inc. and Karo Bio. The advancement of this compound, in clinical development to address an important unmet clinical need, has triggered a significant milestone payment from Merck to Karo Bio.
The collaboration with Merck & Co., Inc. was initiated in November 1997 with the objective of developing new treatments targeting estrogen receptors, which may be particularly relevant in women's healthcare, but also in other major clinical areas.
The joint drug discovery phase of the collaboration with Merck was completed in 2002 and has been successful in the discovery of numerous selective compounds. Merck has exclusive world wide rights to all compounds identified during the collaboration and is responsible for their further preclinical and clinical development. In addition to the most advanced compound, which now has progressed into clinical testing, Merck continues to evaluate additional compounds for potential use in other clinical indications.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Evolva completes Abunda acquisition
Tripos Announces LeadScreen™ 2002, Pre-Formatted Screening Compound Set to Accelerate Drug Discovery by Biotechs
Inion introduces its First Biodegradable Spinal Implant in Europe - CE Mark received for S-1TM Anterior Cervical Fixation System
Dr Barry Buckland Joins the Mucosis Supervisory Board
Beckman Coulter Announces the Creation of Beckman Coulter Genomics - New Company Offers Comprehensive Genomic Services
Scientists remove amyloid plaques from brains of live animals with Alzheimer's disease - New research in the FASEB Journal suggests that manipulation of the brain's own immune cells with IL-6 could lead to reversal of Alzheimer's disease pathology
